

Recombinant Human TNFSF13B/BAFF/CD257 Protein

Catalog No.: RP01730 **Recombinant**

Sequence Information

Species **Gene ID** **Swiss Prot**
 human 10673 Q9Y275

Tags
 N-6His

Synonyms

DTL; BAFF; BLYS; CD257; TALL1; THANK;
 ZTNF4; TALL-1; TNLG7A;
 TNFSF20;TNFSF13B

Product Information

Source **Purification**
 HEK293 cells $\geq 90\%$ as
 determined by SDS-PAGE.

Calculated MW **Observed MW**
 17.88 kDa 19-20 kDa

Endotoxin
 < 0.1 EU/ μ g of the protein by LAL method.

Formulation
 Lyophilized from a 0.22 μ m filtered solution of PBS, pH 7.4.

Reconstitution
 Centrifuge the vial before opening. Reconstitute to a concentration of 0.1-0.5 mg/mL in sterile distilled water. Avoid vortex or vigorously pipetting the protein. For long term storage, it is recommended to add a carrier protein or stabilizer (e.g. 0.1% BSA, 5% HSA, 10% FBS or 5% Trehalose), and aliquot the reconstituted protein solution to minimize freeze-thaw cycles.

Background

B lymphocyte stimulator (BLyS), also known as TNFSF13B, CD257 and BAFF, is a single-pass type II membrane protein, which belongs to the tumor necrosis factor family. BAFF is abundantly expressed in peripheral blood Leukocytes and is specifically expressed in monocytes and macrophages. BAFF is a cytokine and serves as a ligand for receptors TNFRSF13B (TACI), TNFRSF17 (BCMA), and TNFRSF13C (BAFFR). These receptors are a prominent factor in B cell differentiation, homeostasis, and selection. BLyS levels affect survival signals and selective apoptosis of autoantibody-producing B cells. Thus, it acts as a potent B cell activator and has been shown to play an important role in the proliferation and differentiation of B cells. Overexpression of BLyS in mice can lead to clinical and serological features of systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS). BLyS is an attractive therapeutic target in human rheumatic diseases. The ability of BLyS to regulate both the size and repertoire of the peripheral B cell compartment raises the possibility that BLyS and antagonists thereof may form the basis of a therapeutic trichotomy. As an agonist, BLyS protein may enhance humoral immunity in congenital or acquired immunodeficiencies such as those resulting from viral infection or cancer therapy.

Basic Information

Description

Recombinant human TNFSF13B/BAFF/CD257 Protein is produced by HEK293 cells expression system. The target protein is expressed with sequence (Ala134-Leu285) of human TNFSF13B/BAFF/CD257 (Accession #NP_006564.1) fused with a 6 \times His tag at the N-terminus.

Bio-Activity

Measured by its binding ability in a functional ELISA. Immobilized Human TNFSF13B (Catalog: RP01730) at 5 μ g/mL (100 μ L/well) can bind Human TNFRSF17 (Catalog: RP00155) with a linear range of 0.001-2.3 ng/mL.

Shipping

The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below.

Storage

Store at -20°C. Store the lyophilized protein at -20°C to -80 °C up to 1 year from the date of receipt.

After reconstitution, the protein solution is stable at -20°C for 3 months, at 2-8°C for up to 1 week.

Avoid repeated freeze/thaw cycles.


Operational Notes

For your safety and health, please wear a lab coat and disposable gloves for handling.

Contact

	400-999-6126
	cn.market@abclonal.com.cn
	www.abclonal.com.cn

Validation Data



Recombinant Human TNFSF13B/BAFF/CD257 Protein was determined by SDS-PAGE under reducing conditions with Coomassie Blue.

Immobilized Human TNFSF13B (Catalog: RP01730) at 5 μ g/mL (100 μ L/well) can bind Human TNFRSF17 (Catalog: RP00155) with a linear range of 0.001-2.3 ng/mL.